Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Olutasidenib: an Achilles' heel for IDH1-mutated MDS?

Olutasidenib: an Achilles' heel for IDH1-mutated MDS?

Journal: Blood advances
Published: October 20, 2025

Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.

Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.

Journal: Cancers
Published: July 11, 2025

Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast].

Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast].

Journal: Blood and lymphatic cancer : targets and therapy
Published: June 26, 2025

Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast].

Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast].

Journal: Blood and lymphatic cancer : targets and therapy
Published: June 19, 2025

Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm.

Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm.

Journal: Leukemia & lymphoma
Published: June 13, 2025

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Journal: Blood advances
Published: April 07, 2025

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Journal: Blood advances
Published: April 07, 2025

Bioanalytical method development and validation for determination of olutasidenib and its application to pharmacokinetic studies.

Bioanalytical method development and validation for determination of olutasidenib and its application to pharmacokinetic studies.

Journal: RSC advances
Published: February 17, 2025

Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R ⩾3.5 in patients aged 60 or older: current landscape and challenges.

Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R ⩾3.5 in patients aged 60 or older: current landscape and challenges.

Journal: Therapeutic advances in hematology
Published: February 03, 2025

Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms.

Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms.

Journal: British journal of haematology
Published: January 03, 2025

Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.

Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.

Journal: British journal of haematology
Published: December 03, 2024

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

Journal: Journal of hematology & oncology
Published: November 06, 2024
Showing 1-12 of 39

Last Updated: 10/31/2025